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Abstract
Background and Objectives Previous pharmacokinetic
studies of the inhaled corticosteroid, fluticasone furoate (FF),
and the long-acting, beta2-receptor agonist, vilanterol (VI)
have been performed in relatively small populations using
non-compartmental pharmacokinetic methods and censored
data (due to low drug exposure relative to assay sensitivity).
This paper presents a population pharmacokinetic analysis,
utilizing pooled concentration–time data from clinical
studies in healthy subjects and from global trials in
patients with chronic obstructive pulmonary disease
(COPD). The objective of this analysis was to characterize
the population pharmacokinetics of FF and VI following
once-daily inhalation dosing of FF/VI or the individual
components (FF and VI) and to identify significant
covariates that impact systemic exposure to FF and VI in
this population.
Methods Population pharmacokinetic methods that max-
imize the likelihood of all data were developed to describe
systemic exposure to FF and VI following once-daily
FF/VI, FF, or VI, and to identify significant covariates that
impact the pharmacokinetics. COPD patients (N = 1225
for the FF analysis and N = 1091 for the VI analysis; 94
and 93 % of total data, respectively) and healthy subjects
contributed to the analysis.
Results FF data were described by a two-compartment
model with first-order absorption and elimination. The
population grouping ‘‘race’’ was a significant covariate
on inhaled clearance (CL/F). The area under the curve
over 24 h (AUC0–24) for FF was higher for East Asian,
Japanese, and South East Asian (average 23–30 %) and
Asian Central, White Arabic, American Indian/Native
Alaskan, and ‘other’ (10–26 %) subjects compared with
White/Caucasians. VI pharmacokinetics were described
by a three-compartment model with zero-order absorp-
tion and first-order elimination. Significant demographic
covariates identified to affect pharmacokinetics of VI
were age [on CL/F and central volume (V1/F)], body-
weight (on CL/F), sex and smoking (on V1/F).
Conclusions While significant effects of the covariates
were observed in this study, the magnitude of these effects
on systemic exposure is not large enough to warrant FF/VI
dosage adjustment in patients with COPD.
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Key Points
Population pharmacokinetic methods that utilize all
data including those below the lower limit of
quantification were developed to describe fluticasone
furoate (FF) and vilanterol (VI) systemic exposure in
chronic obstructive pulmonary disease (COPD)
patients following once-daily FF/VI, FF, or VI and to
identify significant covariates that impact the
pharmacokinetics.
Race was a significant covariate on inhaled clearance
(CL/F) of FF resulting in a maximum of 30 % higher
in steady-state AUC0–24 for subjects with Asian
heritage compared with White/Caucasians. Age,
bodyweight, sex and smoking status were significant
covariates to affect the pharmacokinetics of VI.
The magnitudes of these covariate effects on
systemic exposure are not large enough to warrant
FF/VI dosage adjustment in patients with COPD.
1 Introduction
Once-daily, combination pharmacological therapies have
the potential to simplify treatment in chronic obstructive
pulmonary disease (COPD) by reducing dosing frequency
whilst increasing compliance [1]. Fluticasone furoate
(FF; GW685698), a novel glucocorticoid, in combination
with vilanterol (VI; GW642444M), a potent, inhaled, long-
acting, beta2-receptor agonist (LABA), is approved for the
maintenance treatment for COPD as BREOTM ELLIP-
TATM (100/25 lg) in the US and for COPD (100/25 lg)
and asthma (100/25 and 200/25 lg) as RELVARTM
ELLIPTATM in the EU. Fluticasone furoate/vilanterol
(FF/VI) is effective at improving lung function in patients
with COPD and has a favorable safety and tolerability
profile [2, 3]. Furthermore, at therapeutic doses, there is
little evidence for the effects of clinical concern previously
reported for inhaled corticosteroids (ICSs; decreased serum
cortisol) [4, 5] or LABAs (hypokalemia, hyperglycemia,
and tachycardia) [6]. However, as with the long-term use of
all ICS, there is an increased risk of pneumonia [7].
The pharmacokinetics of FF and VI following adminis-
tration of FF/VI have been described in healthy subjects [8] as
well as in subjects with COPD [2]. Those studies had the
limitation that they were conducted in relatively small popu-
lations, used non-compartmental pharmacokinetic methods,
and pharmacokinetic profiles were censored due to the low
systemic exposure to FF and VI relative to assay sensitivity.
Appropriate model-based population pharmacokinetic
approaches have been developed to address censoring due to
non-quantifiable data [9]. Using this methodology and inte-
grating pharmacokinetic concentration–time data from global
safety and efficacy studies allowed adequate characterization
of the pharmacokinetic profiles and assessment of the influ-
ence of potential covariates (demographics, baseline charac-
teristics, and co-administered drugs) as sources of
pharmacokinetic variability in the patient population.
This paper presents a population pharmacokinetic
analysis utilizing pooled concentration–time data from
clinical studies in healthy subjects and global trials in
subjects with COPD. Its purpose was to characterize the
population pharmacokinetics of FF and VI following once-
daily inhalation dosing of FF/VI or the individual compo-
nents (FF and VI) to subjects with COPD and identify
significant covariates that impact FF and VI systemic
exposure in this population.
2 Methods
2.1 Subjects and Study Designs
Three Phase III (Study 1 [10]; Study 2 [11]; Study 3 [2])
and one Phase II (Study 4 [3]) multicenter, randomized,
double-blind, placebo-controlled studies in subjects with
COPD were included in the VI meta-analysis (Online
Resource: Table S1). The three Phase III studies (Studies
1, 2, and 3) in subjects with COPD were also included in
the FF meta-analysis. The Phase II study (Study 4) was
not included since there was limited informative data
(only 0–4 h post-dose) defining the pharmacokinetic
profile of FF. The demographics of the subjects with
COPD were generally similar in each study, enabling the
data to be combined for the meta-analysis. A further
Phase I randomized, placebo-controlled investigation
(Study 5 [12]), with intense pharmacokinetic sampling in
healthy subjects, was included in both meta-analyses to
support population pharmacokinetic modeling and stabi-
lize parameter estimation (Online Resource: Table S1).
This Phase I study was chosen because it included both a
therapeutic (200/25 lg) and a supratherapeutic FF/VI
dose (800/100 lg) that provided robust pharmacokinetic
data describing the pharmacokinetic profiles for FF and
VI. In all five studies FF/VI, FF or VI was administered
once daily in the morning.
In Studies 1 and 2, eligible subjects were randomized
(1:1:1:1:1) or (1:1:1:1:1:1) to one of the possible treatments
(FF/VI: 50/25 or 100/25 lg Study 1, 100/25 or 200/25 lg
Study 2; FF: 100 lg Study 1, 100 or 200 lg Study 2; VI
monotherapy (25 lg); or placebo; Online Resource:
Table S1). The planned duration of treatment was
24 weeks. In Study 3, eligible subjects were randomized to
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two of the possible three (50/25, 100/25, 200/25 lg) FF/VI
strengths and placebo for 4 weeks (Online Resource:
Table S1). In study 4, eligible subjects were randomized
(2:1) to one of the two possible treatments (FF/VI
400/25 lg or placebo; Online Resource: Table S1) for
4 weeks. Study 5 was a randomized four-way cross-over
study in which eligible healthy subjects received FF/VI
200/25 lg, FF/VI 800/100 lg, or placebo for 1 week with
a placebo tablet administered on Day 7 and placebo for
1 week with a moxifloxacin single dose on Day 7 (Online
Resource: Table S1). All blinded study medication was
delivered via the ELLIPTATM dry powder inhaler (DPI).
In the Phase II and III studies, eligible subjects (aged
C40 years) had a documented clinical history ofCOPDand a
current or prior history of C10 pack-years of cigarette
smoking at screening. The Phase I study (Study 5) included
healthy, male or female subjects (aged 18–65 years).
All subjects gave written informed consent prior to any
study-related procedures and the protocols were approved
by the appropriate institutional review boards and con-
ducted in accordance with good clinical practice guidelines
and the Declaration of Helsinki.
2.2 Pharmacokinetic Sample Collection
and Bioanalysis
In each investigation, pharmacokinetic samples were col-
lected for the determination of FF and/or VI plasma concen-
trations. Samples were collected at nominal times relative to
the proposed time of FF/VI, FF or VI administration as out-
lined in Table S1 (Online Resource). An intense sampling
approach was utilized in three of the five studies (Studies 3, 4,
and5). The largerPhase III studies (Studies 1 and2)had sparse
pharmacokinetic samples collected pre-dose and within
specific collection windows up to 4 h post-dose (Online
Resource: Table S1). Actual times were recorded and used in
the population pharmacokinetic analysis.
Plasma samples (150 lL aliquot) from all studies were
analyzed for FF by solid phase extraction using [13C2H3]-
GW685698 (FF, as internal standard) followed by high-
performance liquid chromatography with tandem mass
spectrometry using an Applied Biosystems API-5000. A
gradient system using 5 mM ammonium formate and
methanol was run with column ACE 50 9 2.1 mm,
C18 3 lm, Hichrom Ltd (Reading, Berkshire, UK) running
at 45 C. The ion transition for FF was m/z 539–313. The
validation range of the assay was 10–1000 pg/mL for FF.
Within-run precision, between-run precision, and bias were
all B14.3 % over the assay range; the lower limit of
quantification for FF was 10 pg/mL.
Plasma samples (200 lL aliquot) from all studies were
analyzed for VI by solid phase extraction using ([2H12]-
GW642444 [VI] as internal standard) followed by high-
performance liquid chromatography with tandem mass
spectrometry (Applied Biosystems API-5000, Paisley,
Renfrewshire, UK). A gradient system using 10 mM
ammonium formate containing 0.1 % formic acid and
acetonitrile containing 0.1 % formic acid was run with
column 50 9 2.1 mm i.d. Hypersil Gold, 3 lm, Thermo
Scientific running at 50 C. The ion transition for VI was
m/z 486–159. The validation range of the assay was
10–10,000 pg/mL for VI. Within-run precision, between-
run precision, and bias were all B14.4 % over the assay
range; the lower limit of quantification for VI was
10 pg/mL. In Study 3, the VI aliquots for analysis were
smaller than planned. As a consequence, VI samples were
diluted 1 in 2 for analysis, with the result that the VI lower
limit of quantification (LLQ) for this study was raised to
20 pg/mL.
Where reported concentrations were above the higher
limit of quantification, the plasma samples were diluted
(plasma), as appropriate, prior to re-analysis to provide
concentrations within the validated range. Quality controls
prepared at three different concentrations were analyzed
with each batch of samples against separately prepared
calibration standards to assess the day-to-day performance
of the assay. Quality control results from this study met the
acceptance criteria of no more than one-third of the quality
control results deviating from the nominal concentration by
more than 15 %, with at least one quality control result
acceptable at each concentration.
2.3 Population Modeling
All data preparation and presentations were performed
using R (Version 2.10.1 or above) [13]. The FF and VI
concentration–time data were modeled independently.
Nonlinear mixed-effects modeling of the data was con-
ducted using NONMEM version 7.1.2 (ICON Develop-
ment Solutions, Dublin, Leinster, Ireland [14]). The
method selected for minimization was Stochastic Approx-
imation Expectation Maximization (SAEM) with interac-
tion for both the FF and VI analyses. A high proportion of
records reporting both FF and VI concentrations were
below the LLQ (10 or 20 pg/mL) particularly at the lower
doses of FF in the Phase III studies and beyond 2 h post-
dose following VI. Given this and the sparse nature of
sampling, addition of more extensively sampled concen-
tration–time data from a FF/VI study in healthy subjects
(Study 5) at a higher dose (800/100 lg) and also the
highest Phase III dose (200/25 lg) was essential to achieve
an appropriate structural model to describe the data. To
incorporate the large extent of non-quantifiable data in each
dataset, the methodology that maximized the likelihood for
all the data, treating those data below the LLQ (BLQ) as
censored was applied. The data were analyzed using the
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methodology referred to as M3 and the F_FLAG option
and PHI function available in NONMEM v7.1.2 [9]. Pro-
portional and exponential models were evaluated to
describe the inter-individual variability.
Supporting application interfaces for data handling,
exploratory diagnostics, and simulation included Xpose V4
[15], R (2.10.1 or above) [13] and WinNonlin 5.2
(Pharsight, Mountain View, CA, USA).
2.3.1 Covariate Analysis
Covariates were considered only for pharmacokinetic
parameters for which it was plausible that a covariate can
affect that parameter. Covariates were considered signifi-
cant if there was a reduction on the objective function
value (OFV) [C6.64, v2\ 0.01 for 1 degree of freedom
(df)], a smaller AIC and there was no overlap in the 95 %
confidence interval (CI) for the covariate effect (hcov).
The covariates considered for evaluation of their influ-
ence on FF and VI pharmacokinetics included population
(healthy subjects or subjects with COPD), age, weight,
height, sex, ethnicity (hispanic or latino/non-hispanic or non-
latino), bodymass index, race, tobacco use (number of pack-
years), smoking status at screening (former or current),
reversibility at screening (reversible or non-reversible), and
percentage predicted forced expiratory volume in the first
second (PFEV). Due to limited numbers of subjects in some
of the specific race categories, subjects were grouped and
categorized as ‘RACE1’ as follows: RACE1 = 1—White
Caucasian (82 % of the FF and VI dataset); RACE1 = 2—
East Asian, Japanese, and South East Asian (14 % of the FF
and 13 % of the VI dataset); RACE1 = 3—African Amer-
ican (3 % of the FF and VI dataset); RACE1 = 4—Asian
Central, White Arabic, American Indian/Native Alaskan,
and ‘other’ (2 % of the FF and VI dataset).
All five studies included in the meta-analysis for VI used
the same assay method, administered the same dose of VI
(25 lg) and had comparable pharmacokinetic sampling and
patient populations. However, there was a suggestion on
the review of the raw concentration–time data that VI
systemic exposure in study 3 was higher and the study
differences had been previously observed (unpublished
data; GSK, UK). As a result, ‘study’ was also included as a
covariate to describe these differences.
Plots of inter-individual variability (ETA) versus each
covariate were initially used to select potential covariates
for inclusion in the FF pharmacokinetic model and the VI
pharmacokinetic model.
For FF, each potentially significant covariate identified
from the plots was individually included on the fixed
parameter in the base model to identify significant covari-
ates. Next, all significant covariates were added to the base
model. After the full model had been defined, the
significance of each covariate was tested individually by
removing one at a time from the full model. A covariate was
retained in themodel if, upon removal, the OFV increased by
more than 6.64 points (v2\ 0.01 for 1 df). The elimination
steps were repeated until all non-significant covariates were
excluded and the final model was defined.
For VI, potential parameter–covariate relationships were
also tested using a step-wise approach, however, because of
the long computational time, the influence of a covariate on
more than one parameter [such as inhaled clearance (CL/F)
and volume of central compartment (V1/F)] or the effect of
multiple covariates (such as smoking and sex) were exam-
ined within a single step. Plots of ETA versus each covariate
for each intermediate base model were then used to select
additional meaningful covariates for inclusion in the VI
pharmacokinetic model. This process (including addition of
multiple covariates within one step) was repeated for inter-
mediate base models until there were no further meaningful
covariates to be selected from the covariate plots. The
resulting model was considered to be the final model.
2.4 Model Evaluation
The model improvement was evaluated based on goodness-
of-fit criteria such as reduction in the objective function
value (OFV) of C6.64, v2\ 0.01 for 1 df, the agreement
between the observed and predicted concentration values,
and the reduction in pattern of conditional weighted residu-
als. Precision of parameter estimates, scientific plausibility
of parameter estimates, OFV and number of estimated
parameters (Akaike criteria), and decrease in the inter-indi-
vidual and/or residual error were also considered. To eval-
uate the adequacy of the finalmodels, including the effects of
statistically significant covariates, a visual predictive check
procedure [16] was performed. This procedure was con-
ducted as follows: 1000 replicates for the FF original dataset
and 200 replicates for the original VI dataset were simulated
based on the parameter estimates from the final model, and a
95 % prediction interval was computed based on the simu-
lated datasets. The observed plasma concentration–time data
were plotted on the prediction interval to visually assess the
concordance between the simulated and observed data. In
addition, the observed proportion of the data BLQ was
plotted with the model prediction interval for proportion of
the BLQ data to visually assess the concordance between the
simulated and observed BLQ data.
2.5 Model Predicted Systemic Exposure
Individual post hoc estimates of CL/F from the final pop-
ulation pharmacokinetic models were used to derive indi-
vidual AUC0–24 values (ratio of nominal dose/individual
post hoc estimate of CL/F). Concentration–time profiles
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were simulated using the parameter estimates from the final




3.1.1 Subject Demographics and Plasma Concentrations
The demographic characteristics of the subjects included in
the FF analysis are summarized in Table S2 (Online
Resource). A total of 1307 subjects (healthy subjects or
subjects with COPD) were included in the FF pharma-
cokinetic dataset. The vast majority (94 %) were subjects
with COPD. In total, there were 11,789 observations of
which 39 % were reported as BLQ (\10 pg/mL). Scatter
plots of observed FF concentrations relative to the time of
the last dose are presented by treatment in Fig. S1 (Online
Resource). FF could be quantified ([10 pg/mL) in the
majority (C53 %) of samples collected up to 6 h post-dose
(FF 100 and 200 lg and FF/VI 100/25 and 200/25 lg).
Beyond 6 h post-administration, there was limited FF
concentration data in subjects with COPD. Trough (pre-
dose) FF concentrations were BLQ in the majority ([58 %)
of samples. Following FF/VI 50/25 lg to subjects with
COPD, the majority (72 %) of samples were BLQ. FF was
quantifiable in the majority of healthy subjects at all
timepoints after both FF/VI 200/25 and 800/100 lg.
3.1.2 Fluticasone Furoate Pharmacokinetic Model
The pharmacokinetics of FF were well described by a two-
compartment model with first-order absorption and first-
order elimination (ADVAN4, TRANS4). Due to the very
high proportion of non-quantifiable data for 50/25 lg, this
treatment was excluded from the model building process
after initial runs were unsuccessful. Once the final model
was obtained, this model and the base model were re-run
including all treatments. For the structural base model, the
volume of the central compartment (V2/F) was fixed to a
value appropriate for central V2 (1.36 L) following evalu-
ation of a range of values (unpublished data, GSK, UK,
2012) and the residual error model was additive.
The only covariate found to be significant was ‘‘race’’ on
inhaled clearance (CL/F). The relationship between CL/F
and the categorical covariate RACE1 (COV) was described
using the following model:
Lnh ¼ h1 þ COV
where h was the population estimate and h1 was the pop-
ulation estimate for RACE1 = 1 and ‘‘COV’’ was the
fixed-effect parameter for each ‘‘race’’ category
(RACE1 = 1—White; RACE1 = 2—East Asian, Japa-
nese and South East Asian; RACE1 = 3—African Amer-
ican; RACE1 = 4—Asian Central, White Arabic,
American Indian/Native Alaskan and ‘other’).
The parameter estimates for the final model are pre-
sented in Table 1. The majority of fixed-effect parameters
(THETAs) were estimated with reasonable precision
(\30 %). The fixed-effect parameters RACE1 = 3 and
RACE1 = 4 on CL/F were estimated with less precision
[% relative standard error (RSE) 199 % for RACE1 = 3
and 51 % for RACE1 = 4). However, it should be noted
that RACE1 = 3 and RACE1 = 4 groups represented a
small proportion of the total population (B3 %) of the FF
dataset. Inter-individual variances (exponential model)
were estimated with reasonable precision (%RSE B36 %).
An additive error model described the residual variability.
The typical value of CL/F was 230 L/h for a white
Caucasian subject with COPD. In comparison, CL/F was
lower in subjects categorized as RACE1 = 2 (East Asian,
Japanese, and South East Asian) and RACE1 = 4 (Asian
Central, White Arabic, American Indian/Native Alaskan,
and ‘other’) (186 and 176 L/h, respectively) and slightly
higher (244 L/h) for subjects categorized as RACE1 = 3
(African American), although it should be noted that the
fixed-effect parameter RACE1 = 3 was estimated with less
precision (%RSE 199 %) and should thus be interpreted
with caution.
3.1.3 Fluticasone Furoate Model Evaluation
The goodness-of-fit of the final model for FF, including
records from the 50/25 lg dose, was assessed by a
graphical approach (Fig. 1). The visual predictive checks
for the FF final model showed that the majority of the data
were captured within the prediction interval that encom-
passes 90 % of the population as indicated by the 5th and
95th percentiles (Fig. 2). The models also generally
described the proportion of BLQ data (Fig. 2).
3.2 Vilanterol
3.2.1 Subject Demographics and Plasma Concentrations
The demographic characteristics of the subjects included in
the VI meta-analysis are summarized in Table S2 (Online
Resource). A total of 1167 subjects (healthy subjects or
subjects with COPD) were included in the VI pharma-
cokinetic dataset. The vast majority (94 %) were subjects
with COPD. In total, there were 10,807 observations of
which 30 % were reported as BLQ (B20 pg/mL). Scatter
plots of observed VI concentrations relative to the time of
the last dose are presented by treatment in Fig. S1 (Online
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Resource). Where the VI LLQ was 10 pg/mL (Studies 1, 2,
and 3), VI could be quantified in the majority (C81 %) of
samples up to 4 h post-dose (i.e., last sampling time/win-
dow) following administration to subjects with COPD.
Reflecting the higher LLQ (20 pg/mL) in Study 4, VI
plasma concentrations were BLQ in the majority (C53 %)
of samples by 3 h post-dose and in C84 % of samples by
6 h after dosing. Overall, there was very limited VI con-
centration–time data defining the VI pharmacokinetic
profile in subjects with COPD beyond 4 h post-adminis-
tration. Following FF/VI (200/25 lg) to healthy subjects
C50 % of samples were BLQ by 2 h post-dose. At the
fourfold higher VI dose (FF/VI; 800/100 lg), profiles were
well defined with C68 % of the samples having quantifi-
able concentrations of VI at trough.
3.2.2 Vilanterol Pharmacokinetic Model
VI concentration–time profiles reflected rapid attainment of
VI Cmax following oral inhalation but provided little data to
define the absorption phase (Online Resource: Fig. S1).
Whilst first-order absorption models were explored, using
intense sampling concentration–time profiles from healthy
subjects, zero-order absorption appeared to better describe
the data. Based on the observed concentration–time profiles,
and initial model building, a three-compartment linear
model with zero-order absorption and first-order elimination
was found to adequately describe the data (ADVAN11,
TRANS4). For the structural base model, CL/F, V1/F, vol-
ume of the peripheral compartment (V2/F), and residual
error were separated by population (subjects with COPD or
healthy subjects); inter-subject variability on D1, Q2/F, and
V2/F was fixed and residual error was additive.
The final population pharmacokinetic model incorpo-
rated the effect of age, weight, and study (Study 4) on
CL/F and age, smoking, sex, and study (Studies 3 and 4) on
V1/F for subjects with COPD.
The effect of a categorical covariate [e.g., sex
(males = 1, females = 2)] was evaluated for its influence
on the population mean values as follows:





Parameter Ln estimate (95 % CI) Estimate (95 % CI) RSE (%)
CL/F (L/h) 5.44 (5.39, 5.49) 230 (219, 242) 0.47
V2/F (L) 0.31 FIXED 1.36 FIXED FIXED
Q/F (L/h) 5.59 (5.40, 5.78) 268 (221, 324) 1.73
V3/F (L) 4.71 (4.51, 4.91) 111 (90.9, 136) 2.21
ka (h
-1) -2.95 (-3.01, -2.89) 0.0523 (0.0493, 0.0556) 1.06
RACE1 = 2 on CL/F -0.211 (-0.329, -0.0930) 0.810 (0.720, 0.911) 28.5
RACE1 = 3 on CL/F 0.0602 (-0.175, 0.295) 1.062 (0.839, 1.343) 199.0
RACE1 = 4 on CL/F -0.265 (-0.528, -0.002) 0.767 (0.590, 0.998) 50.6
CI confidence interval, RSE relative standard error, CL/F inhaled clearance, V2/F volume of central
compartment, Q/F intercompartmental clearances, V3/F volumes of peripheral compartment, ka absorption
rate
RACE1 = 2—East Asian, Japanese, and South Asian; RACE1 = 3—African American; RACE1 = 4
Asian Central, White Arabic, American Indian/Native Alaskan, and other
Fig. 1 Goodness-of-fit plots for
the fluticasone furoate final
model in subjects with COPD
(solid line is the line of identity
as a reference and the dashed
line is the loess smooth). COPD
chronic obstructive pulmonary
disease, FF fluticasone furoate
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Fig. 2 Visual predictive check plots stratified by dose regimen
(a = 50 lg, b = 100 lg, and c = 200 lg) for the final fluticasone
furoate model; concentration versus time [observed median (dashed
line), prediction intervals for median, 5th and 95th percentiles
(shaded areas)] and the proportion of BLQ values by time [observed
median (dashed line), prediction intervals for median, 5th and 95th
percentiles (shaded areas)]. BLQ below the lower limit of quantifi-
cation, LLQ lower limit of quantification, RACE1 = 1 White Cau-
casian, RACE1 = 2 East Asian, Japanese, and South East Asian,
RACE1 = 3 African American, RACE1 = 4 Asian Central, White
Arabic, American Indian/Native Alaskan, and other
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LnCL ¼ h1 þ hCOV  ðcovariate  1Þ:
The effect of a continuous covariate (e.g., weight) was
evaluated for its influence on the population mean values as
follows:
LnCL ¼ h1 þ hCOV  ðcovariate  1Þ:
The parameter estimates for the final model are presented
in Table 2. The majority of fixed-effect parameters
(THETAs) were estimated with reasonable precision
(\27 %). The fixed-effect parameters, age, sex, and study
on V1/F, were estimated with less precision (%RSE
35–48 %). Inter-individual variances (exponential model)
were estimated with reasonable precision (%RSE B25 %),
with exception of ETA on volume of the peripheral com-
partment (V3/F) where %RSE was 64 %. An additive error
model described the residual variability.
The typical value of CL/Fwas 94.6 L/h for a subject with
COPD (aged 60 years and weighing 70 kg) within the Phase
III studies (Studies 1, 2, and 3). For these subjects, therewas a
decrease (27 %) in CL/F over the observed age (range
41–84 years), and a reduction (47 %) in inhaled clearance is
also predicted with decreasing bodyweight (range of
160–35 kg). In Study 4, the typical value of CL/F (59.4 L/h)
was predicted to be lower (37 %; COPD subjects aged
60 years and weighing 70 kg) and the predicted decrease in
CL/Fwith decreasing body weight or increasing age (47 and
27 %, respectively)was consistentwith that predicted for the
Phase III studies (Studies 1, 2, and 3).
For V1/F, age, sex, smoking, and study (Studies 3 and 4)
are significant covariates for subjects with COPD. The
central volume (V1/F) was found to decrease (30 %) with
increasing age (41–84 years), to be lower (12 %) in
females, and to be increased with smoking (34 %). The
typical value for V1/F (non-smoking male, aged 60 years)
is predicted to be 639 L (Studies 1 and 2), 447 L (Study 3)
and 185 L (Study 4).
3.2.3 Vilanterol Model Evaluation
The goodness-of-fit of the final model for VI was assessed
by a graphical approach (Fig. 3). The visual predictive
checks for the VI model showed that the majority of the
data were captured within the prediction interval that
encompasses 90 % of the population as indicated by the
5th and 95th percentiles (Fig. 4). The models also gener-
ally described the proportion of BLQ data (Fig. 4),
although there was a trend to underpredict the proportion of
VI BLQ data at early timepoints (\2 h post-dose) in
Studies 1, 2, and 4.
4 Discussion
A two-compartment model with first-order absorption and
first-order elimination described the pharmacokinetics of
FF following inhaled administration via ELLIPTATM DPI




Parameter Ln estimate (95 % CI) Estimate (95 % CI) RSE (%)
CL/F, HVT (L/h) 4.91 (4.81, 5.01) 135.6 (122.7, 149.9) 1.06
CL/F, COPD (L/h) 4.55 (4.51, 4.59) 94.6 (90.9, 98.5) 0.41
Study 4 on CL/F, COPD -0.465 (-0.633, -0.297) 0.628 (0.531, 0.743) 18.5
Age on CL/F, COPD -0.433 (-0.660, -0.206) 0.649 (0.517, 0.814) 26.8
Wt on CL/F, COPD 0.421 (0.286, 0.556) 1.52 (1.33, 1.74) 16.4
V1/F, HVT (L) 5.07 (4.97, 5.17) 159.2 (144.0, 175.9) 0.99
V1/F, COPD (L) 6.46 (6.37, 6.55) 639.0 (584.1, 699.2) 0.74
Study 4 on V1/F, COPD -1.24 (-1.51, -0.968) 0.289 (0.221,0.380) 11.2
Age on V1/F, COPD -0.499 (-0.911, -0.087) 0.607 (0.402, 0.917) 42.1
Smoking on V1/F, COPD 0.295 (0.179, 0.411) 1.34 (1.20, 1.51) 20.1
Sex on V1/F, COPD -0.128 (-0.25, -0.006) 0.880 (0.779, 0.994) 48.4
Study 3 on V1/F, COPD -0.358 (-0.601, -0.115) 0.699 (0.548, 0.891) 34.6
Q2/F (L/h) 5.49 (5.39, 5.59) 242.3 (219.2, 267.7) 0.94
V2/F, HVT (L) 6.23 (6.03, 6.43) 507.8 (415.7, 620.2) 1.65
V2/F, COPD (L) 5.18 (5.03, 5.33) 177.7 (152.9, 206.4) 1.52
Q3/F (L/h) 4.95 (4.83, 5.07) 141.2 (125.2, 159.2) 1.26
V3/F (L/h) 7.65 (7.58, 7.72) 2100.6 (1958.6, 2253.0) 0.43
D1 (h) -2.32 (-2.39, -2.25) 0.098 (0.092, 0.105) 1.63
CI confidence interval, CL/F inhaled clearance, COPD chronic obstructive airways disease, HVT healthy
volunteers, RSE relative standard error, Wt weight, V1/F volume of central compartment, Q2/F and Q3/F,
intercompartmental clearances; V2/F, V3/F volumes of peripheral compartment; D1 input duration
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as FF/VI or FF alone. The final pharmacokinetic model was
used to derive individual estimates and summary statistics
of FF steady-state systemic exposure (Cmax and AUC0–24)
across the COPD population (Table 3). Based on the model
predictions, there were no notable differences in FF
exposure between individual component (FF) versus
combination treatment (FF/VI; Table 3). This finding is
consistent with a lack of an effect of combination treatment
with FF/VI on FF pharmacokinetics following adminis-
tration of FF/VI and FF to healthy subjects [8]. For those
subjects recruited to the large global Phase III trials, sys-
temic exposure was predicted to increase in an approxi-
mately proportional manner with FF dose (either as a
monotherapy or as a FF/VI combination treatment; 50/25,
100/25 and 200/25 lg) (Table 3). It should be noted that
average systemic exposure following a low dose of FF (FF
50 lg or FF/VI 50/25 lg) is predicted to be BLQ of the
analytical assay (10 pg/mL).
The relevance of the only significant covariate (‘‘race’’)
on FF exposure in patients with COPD was also assessed by
simulations of individual steady-state AUC0–24 (Table 3).
For East Asian, Japanese, and South East Asian subjects,
predicted FF AUC0–24 was on average 23–30 % higher
compared with white Caucasians. This finding is consistent
with higher FF systemic exposure seen previously in heal-
thy subjects of East Asian origin following inhaled
administration [17]. In the healthy subject study, there was
no evidence for a difference in CYP3A4 activity (as mea-
sured by both urine cortisol:6-b-hydroxy cortisol ratio and
plasma 4-b-hydroxy-cholesterol) between Chinese, Japa-
nese and Korean subjects compared with Caucasians [17].
In addition, given the high capacity of the CYP3A4 system
and the low clinical dose of FF, any potential differences in
enzyme expression would not be anticipated to explain the
differences in CL/F. Furthermore, there were no marked
differences in the inherent pharmacokinetics of FF follow-
ing intravenous FF 250 lg between ethnic groups, other
than those accounted for by body weight differences [17].
Also, FF is not anticipated to be a substrate of anion or
cation transporters, and although FF is a substrate of the
transporter P-glycoprotein, inter-ethnic differences in
activity are not anticipated. Thus, the exact reasons for these
differences are not known but could be a consequence of
differences in mucociliary clearance, lung solubility, and/or
regional lung disposition of inhaled FF. Despite the higher
FF systemic exposure for East Asian, Japanese, and South
East Asian patients with COPD, the predicted FF AUC0–24
following all FF treatments was below levels
(1000 pgh/mL) which are considered to be the threshold
for significant cortisol suppression (a 20 % reduction) in
placebo-controlled studies [18]. For subjects categorized as
Asian Central, White Arabic, American Indian/Native
Alaskan, and ‘other’, estimates of FF AUC0–24 were on
average 10–26 % higher compared with white Caucasian
subjects although it should be noted that the numbers of
subjects in this race category were low at each dose (\2 %
in the FF dataset; Table 3) and the parameters were not well
estimated.
A three-compartment model with zero-order absorption
and first-order elimination described the pharmacokinetics
of VI following inhaled administration via ELLIPTATM
DPI as FF/VI or VI alone. Due to the fast absorption fol-
lowing inhalation and sampling times specified for phar-
macokinetic analysis, a zero-order absorption model was
found to be better in terms of model selection compared to
a first-order absorption model. However, this was largely
data driven.
The final model was used to derive individual estimates
and summary statistics of VI steady-state systemic expo-
sure (Cmax and AUC0–24) across the COPD population
(Table 4). Comparison of the model predicted systemic
exposure showed no difference between individual com-
ponent versus combination treatment (Table 4). This is
consistent with a lack of an effect of combination treatment
on VI pharmacokinetics following administration of FF/VI
and VI to healthy subjects [8]. Age, weight, sex, and
Fig. 3 Goodness-of-fit plots for
the vilanterol final model in
subjects with COPD (solid line
is the line of identity as a
reference and the dashed line is
the loess smooth). COPD
chronic obstructive pulmonary
disease
Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol 751
smoking were significant covariates on the pharmacoki-
netics of VI in subjects with COPD. However, there
appeared to be no notable difference in VI systemic
exposure for males compared with females (Table 4) and
current smokers were predicted to have only slightly lower
AUC(0–24) and Cmax compared with former smokers (5 and
22 %, respectively; Table 4). Furthermore, there was no
notable trend in predicted systemic exposure with
increasing age or decreasing bodyweight (Online Resource:
Fig. S2). The decrease in CL/F with age may in part reflect
declining renal function in the elderly. Whilst severe renal
impairment has no apparent clinically relevant effects on
the pharmacokinetic or pharmacodynamic properties or
tolerability of FF/VI, the ratio of adjusted means (renal
impairment/healthy subjects) for VI AUC0–24 was 1.56
[19], consistent with a small effect of declining renal
function on VI CL/F.
Whilst Studies 3 and 4 were both identified as significant
covariates on the pharmacokinetics of VI, the predicted
pharmacokinetics of VI was only notably different in the
Phase II trial (Study 4; Table 4). As a result of lower
CL/F and a smaller V1/F, the VI exposure was predicted to
be higher (approximately 1.5-fold higher AUC0–24 and 2.7-
fold higher Cmax). This Phase II study represented a small
Fig. 4 Visual predictive check plots stratified by study for the final
vilanterol model; observation [LN concentration (pg/mL)] versus time
and the proportion of BLQ values by time. Observed median (solid
line), 5th, and 95th percentiles (dashed line) and prediction intervals
for median, 5th, and 95th percentiles (shaded areas). BLQ below the
lower limit of quantification, LLQ lower limit of quantification
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Table 3 Model predicted
systemic exposure [geometric
mean (95 % CI)] for fluticasone
furoate [FF; Cmax and AUC0–24]
following administration of FF
(as FF/VI or FF) in subjects
with COPD (Studies 1, 2, and 3)
and predicted AUC0–24 by race
category
Treatment (lg) Population/race N Cmax (pg/mL) AUC0–24 (pgh/mL)
100/25 COPD 391 11.96 (10.94, 12.99) 182.15 (169.61, 194.69)
100 FF COPD 333 11.46 (10.54, 12.38) 181.44 (167.01, 195.87)
200/25 COPD 234 20.30 (18.41, 22.18) 288.02 (260.78, 315.27)
200 FF COPD 168 23.60 (20.83, 26.37) 309.58 (284.51, 334.65)
FF dosea
50 COPD 231 7.52 (6.52, 8.52) 82.92 (75.57, 90.28)
100 COPD 724 11.73 (11.03, 12.43) 181.82 (172.61, 191.04)
200 COPD 402 21.62 (20.02, 23.22) 319.69 (301.42, 337.96)
FF dosea/RACE1b
50 1 174 – 79.05 (71.61, 86.49)
2 37 – 102.77 (79.00, 126.54)
3 16 – 81.19 (43.13, 119.25)
4 4 – 99.25 (75.72, 122.77)
100 1 591 – 176.04 (165.98, 186.10)
2 111 – 223.04 (198.14, 247.95)
3 13 – 128.25 (94.85, 161.65)
4 9 – 202.34 (140.45, 264.24)
200 1 362 – 319.68 (299.78, 339.58)
2 20 – 394.61 (350.67, 438.55)
3 17 – 245.42 (207.09, 283.75)
4 3 – 352.68 (248.13, 457.23)
AUC0–24 area under the curve during 24 h, Cmax maximum plasma concentration, COPD chronic
obstructive pulmonary disease, FF fluticasone furoate, VI vilanterol
a Administered as FF/VI or FF
b RACE1 = 1—White Caucasian; RACE1 = 2—East Asian, Japanese, and South Asian; RACE1 = 3—
African American; RACE1 = 4—Asian Central, White Arabic, American Indian/Native Alaskan, and
other
Table 4 Model predicted
systemic exposure [geometric
mean (95 % CI)] for VI [Cmax
and AUC0–24] following 25 lg
VI (as FF/VI or VI) in subjects
with COPD
Study N Cmax (pg/mL) AUC0–24 (pgh/mL)
All studiesa 1091 43.2 (41.8, 44.6) 265.7 (259.5, 271.9)
HZC112206 (Study 1) 496 43.2 (41.4, 45.1) 273.7 (264.5, 283.3)
HZC112207 (Study 2) 506 39.3 (37.5, 41.3) 251.1 (243.2, 259.4)
HZC110946 (Study 3) 50 49.7 (43.4, 57.1) 249.2 (219.6, 282.8)
HZC111348 (Study 4) 39 120.5 (103.8, 139.8) 408.2 (365.3, 456.1)
Sex
Female 42.1 (40.5, 43.8) 263.8 (256.4, 271.4)
Male 45.7 (42.9, 48.6) 269.8 (259.1, 281.0)
Smoking status
Former 49.4 (47.0, 51.9) 272.8 (263.8, 282.2)
Current 38.3 (36.8, 40.0) 259.5 (251.3, 267.9)
Treatment
Vilanterolb 714 42.3 (40.7, 44.0) 261.6 (254.1, 269.0)
Fluticasone furoate/vilanterolc 338 40.1 (37.9, 42.4) 261.2 (250.6, 272.3)
AUC0–24 area under the curve during 24 h, CI confidence interval, Cmax maximum plasma concentration,
COPD chronic obstructive pulmonary disease, FF fluticasone furoate, VI vilanterol
a All studies (Studies 1, 2, 3 and 4) and FF/VI strengths (50/25, 100/25, 200/25, 400/25 lg)
b 25 lg VI
c 200/25, 100/25 and 50/25 lg FF/VI
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number of subjects (N = 39) with COPD compared with
the larger Phase III population (N = 1052 subjects with
COPD; Table 4). The timing of the pharmacokinetic
sample collection in this Phase II study was almost iden-
tical to that for one of the Phase III trials (Study 3). Fur-
thermore, the demographic characteristics in the Phase II
study were also consistent with the Phase III population
[other than a slightly higher post-albuterol/salbutamol
FEV1 % predicted at screening (58 vs. 46–49 %, respec-
tively), a higher % of subjects who were reversible (51 vs.
24–30 %, respectively) and a lower % of subjects who
were current smokers (25 vs. 52–84 %, respectively)]. The
only other difference was that subjects in this study
received 400/25 lg FF/VI compared with 50/25, 100/25 or
200/25 lg FF/VI in the Phase III investigations although
there is no evidence to suggest that FF affects the phar-
macokinetics of VI [8]. Therefore, the reason for this
marked study difference is not clear and may just reflect
between-study variability. Whilst the systemic exposure
was higher in the Phase II trial, the VI Cmax values esti-
mated for subjects with COPD (geometric mean
120 pg/mL) were consistent with those estimated for
healthy subjects using non-compartmental methods in
Study 5 (geometric mean 115 pg/mL) [12] following
200/25 lg FF/VI; a dose that did not have a significant
effect on the QTc interval as measured by either QTcF or
QTci. Furthermore, predicted VI AUC(0–24) (geometric
mean 408 pgh/mL) for Study 4 was notably lower than
values estimated for healthy subjects using non-compart-
mental methods in Study 5 (geometric mean 775 pg/mL)
following 800/100 lg FF/VI which was well tolerated [12].
Potential inter-study variations in VI systemic exposure
are, therefore, not considered to be a safety concern.
Despite the use of sensitive analytical methods (LLQ
10 pg/ml), there was still a significant proportion of data
below the LLQ for both FF and VI. The methodology that
maximized the likelihood for all the data, treating those
data below the LLQ as censored (M3 method) [20], was
utilized for both analyses; since it has been reported in the
literature, this method provides the most accurate and
precise parameter estimates [9] and enabled robust mod-
eling of the data and evaluation of potential covariates
affecting the pharmacokinetics of FF and VI.
5 Conclusion
Integration of data from global safety and efficacy studies
defined influential covariates on the pharmacokinetics of
FF and VI in subjects with COPD. The population group-
ing defined as ‘‘race’’ was the only significant covariate
identified to affect the pharmacokinetics of FF (CL/F).
Significant demographic covariates identified to affect the
pharmacokinetics of VI were age (on CL/F and V1/F),
bodyweight (on CL/F), sex, and smoking (on V1/F). The
magnitude of the covariate effects on systemic exposure is
not large enough to warrant FF/VI dosage adjustment in
subjects with COPD.
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